Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025
Published: November 29, 2025 Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 riding a powerful wave of oncology wins, big‑ticket acquisitions and fresh analyst upgrades that have pushed the stock to new 52‑week highs. As of the close on Friday, November 28, Merck shares finished at $104.83, just off a record intraday high of $105.84 set earlier in the week.StockAnalysis+1 The stock is up roughly 21% over the past month and about 7–8% year‑to‑date, according to recent performance data and independent valuation analysis.Simply Wall St+2FinanceCharts+2 Today’s update pulls together the most important Merck stock news